Trestolonacetat CAS:6157-87-5

Trestolonacetat(MENT) ist eigentlich eine ganz gut aussehende Droge. Es zeigt keine große Wechselwirkung mit Sexualhormon-bindendem Globulin, Das bedeutet, dass ein großer Teil ungebunden und aktiv im Blut bleiben sollte. Ebenfalls, Das Medikament bindet stark an den Androgenrezeptor, während es eine minimale Affinität zu den Progesteron- bzw. Mineralocorticoid-Rezeptoren zeigt. Since it is not able to be 5a-reduced into a dihydro-version. It likely wouldn’t cause many of the side effects commonly associated with Dihydrotestosterone. This is also a likely reason that it is less apt to cause prostate enlargement, and may even be indicated for the treatment of specific prostate issues. The ability of 7 alpha-methyl-19 nortestosterone acetate (MENT) to increase the weights of ventral prostate and seminal vesicles of castrated rats was four times higher than that of testosterone, while its effect on the weights of bulbocavernosus plus levator ani muscles (Muskel), War 10 times that of testosterone.

Various forms of MENT in human pharmaceutical preparations and devices for contraception and hormone therapy, specifically MENT Ac implant and MENT transdermal gel and patch formulations, are currently under clinical investigation. MENT is absorbed transdermally up to three times the rate of testosterone – 17 methyl testosterone and 17-α methyl testosterone.

MENT will have application in a wide range of indications beyond androgen replacement therapy and contraception, einschließlich, without limitation, primary hypogonadism, testicular failure, ASIH, baldness, sarcopenia, loss of bone mass, muscle wasting and cachexia, BPH, prostate cancer and of course, bodybuilding and sports performance enhancement.

Trestolone acetate is the chemical name of active ingredient in MENT. MENT is a registered trademark of Population Council, Inc. in the United States and/or other countries.